This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chatterjee, K. Search for Related Content PubMed PubMed Citation Articles by Chatterjee, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CARVEDILOL ENALAPRIL MALEATE Medline Plus Health Information Heart Failure

(Circulation. 1996;94:2689-2693.)
© 1996 American Heart Association, Inc.

Articles

Heart Failure Therapy in Evolution

Kanu Chatterjee, MB, FRCP

the Division of Cardiology, University of California, and the Cardiovascular Research Institute, San Francisco.

Correspondence to Kanu Chatterjee, MB, FRCP, Lucie Stern Professor of Cardiology, Vilensky Research Professor of Cardiology, Box 0124, University of California, San Francisco, CA 94143-0124.

Key Words: Editorials • heart failure • carvedilol • receptors, adrenergic, beta • angiotensin

	Introduction

 
During the past 25 years, considerable progress has been made in our understanding of the pathophysiological mechanisms for the development and progression of the heart failure syndrome. On the basis of this growing knowledge, a number of therapeutic approaches have been proposed and tested for the long-term management of chronic heart failure. One of the reasons for the continuing search for newer therapies is to improve prognosis further than achievable with an established therapy. It has been amply documented that clinical heart failure resulting from impaired left ventricular systolic function is associated with a substantial mortality and morbidity and that the more severe the clinical heart failure is, the worse the prognosis. Before the introduction of vasodilator and ACE inhibitor therapy, a 1-year mortality rate of 50% was observed with conventional therapy in patients with severe chronic heart failure.¹ In the CONSENSUS I trial,² in which patients with severe heart failure (NYHA functional class IV) were randomized to receive placebo or enalapril (an ACE inhibitor) in addition to contemporary conventional treatment (digitalis and diuretics), the mortality rates with conventional treatment at 6 months and 12 months were 44% and 54%, respectively. The prognosis of patients who initially present with mild to moderate clinical heart failure and are treated conventionally was assessed in the VA Heart Failure Trial I.³ The cumulative mortality rate of these patients over a period of 48 months was 53.6%. The realization that conventional treatment of established clinical heart failure with digitalis and diuretics is associated with . . . [Full Text of this Article]

This article has been cited by other articles:

				S. K. Hamlin, P. S. Villars, J. T. Kanusky, and A. D. Shaw Role of Diastole in Left Ventricular Function, II: Diagnosis and Treatment Am. J. Crit. Care., November 1, 2004; 13(6): 453 - 466. [Abstract] [Full Text] [PDF]

				M. Taccetta-Chapnick Using Carvedilol to Treat Heart Failure Crit. Care Nurse, April 1, 2002; 22(2): 36 - 58. [Full Text] [PDF]

				L. A. Saxon, T. De Marco, J. Schafer, K. Chatterjee, U. N. Kumar, and E. Foster Effects of Long-Term Biventricular Stimulation for Resynchronization on Echocardiographic Measures of Remodeling Circulation, March 19, 2002; 105(11): 1304 - 1310. [Abstract] [Full Text] [PDF]

				M. R. Bristow {beta}-Adrenergic Receptor Blockade in Chronic Heart Failure Circulation, February 8, 2000; 101(5): 558 - 569. [Full Text] [PDF]

				P. M. Diller, D. R. Smucker, B. David, and R. J. Graham Congestive Heart Failure Due to Diastolic or Systolic Dysfunction: Frequency and Patient Characteristics in an Ambulatory Setting Arch Fam Med, September 1, 1999; 8(5): 414 - 420. [Abstract] [Full Text] [PDF]

				M. L. Kukin, J. Kalman, R. H. Charney, D. K. Levy, C. Buchholz-Varley, O. N. Ocampo, and C. Eng Prospective, Randomized Comparison of Effect of Long-Term Treatment With Metoprolol or Carvedilol on Symptoms, Exercise, Ejection Fraction, and Oxidative Stress in Heart Failure Circulation, May 25, 1999; 99(20): 2645 - 2651. [Abstract] [Full Text] [PDF]

				D. V. Exner, D. L. Dries, M. A. Waclawiw, B. Shelton, and M. J. Domanski Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction J. Am. Coll. Cardiol., March 15, 1999; 33(4): 916 - 923. [Abstract] [Full Text] [PDF]

				D. L. Dries, D. V. Exner, B. J. Gersh, H. A. Cooper, P. E. Carson, and M. J. Domanski Racial Differences in the Outcome of Left Ventricular Dysfunction N. Engl. J. Med., February 25, 1999; 340(8): 609 - 616. [Abstract] [Full Text] [PDF]